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Cell biologists have been afforded extraordinary new op-
portunities for experimentation by the emergence of pow-
erful technologies that allow the selective manipulation of
gene expression. Currently, RNA interference is very
much in the limelight; however, signiﬁcant progress has
also been made with two other approaches. Thus, anti-
sense oligonucleotide technology is undergoing a resur-
gence as a result of improvements in the chemistry of
these molecules, whereas designed transcription factors
offer a powerful and increasingly convenient strategy for
either up- or down-regulation of targeted genes. This
mini-review will highlight some of the key features of
these three approaches to gene regulation, as well as
provide pragmatic guidance concerning their use in cell
biological experimentation based on our direct experi-
ence with each of these technologies. The approaches
discussed here are being intensely pursued in terms of
possible therapeutic applications. However, we will re-
strict our comments primarily to the cell culture situation,
only brieﬂy alluding to fundamental differences between
utilization in animals versus cells.
 
Antisense oligonucleotides
 
The ability of antisense oligonucleotides to suppress gene ex-
pression was discovered more than 25 yr ago (Zamecnik and
Stephenson, 1978). For a decade or more thereafter, antisense
was viewed as a promising tool for selective gene regulation in
experimental and therapeutic situations. However, despite
massive efforts, the therapeutic potential of antisense oligonu-
cleotides has yet to be fully achieved, and their use as routine
laboratory  tools has encountered difficulties. The basis for
these problems lie mainly with the chemistry of early “first
generation” antisense compounds, which are now being super-
seded by newer second or third generation molecules with
improved characteristics.
 
Basic mechanisms and the role of chem-
ical modifications.  
 
Antisense oligonucleotides base
pair with mRNA and pre-mRNAs and can potentially interfere
with several steps of RNA processing and message translation,
including splicing, polyadenylation, export, stability, and protein
translation (Sazani and Kole, 2003; Crooke, 2004). However, the
two most powerful and widely used antisense strategies are the
degradation of mRNA or pre-mRNA via RNaseH and the alter-
ation of splicing via targeting aberrant splice junctions. These
two strategies are based on very distinct oligonucleotide chem-
istries, as discussed below.
RNaseH recognizes DNA/RNA heteroduplexes and
cleaves the RNA approximately midway between the 5
 
 
 
 and 3
 
 
 
ends of the DNA oligonucleotide. This event takes place in the
nucleus. Additional enzymatic processes rapidly degrade the
cleaved RNA, whereas the DNA oligonucleotide can recycle
and participate in further rounds of scission and degradation
(Crooke, 2000). RNaseH requires a B-type heteroduplex and
does not cleave RNA/RNA A-type duplexes (Fig. 1). Standard
phosphodiester oligonucleotides as well as phosphorothioates,
which are first generation chemically modified forms, effec-
tively trigger RNaseH-mediated cleavage. Unfortunately, phos-
phodiester oligonucleotides are extremely unstable in cells,
whereas phosphorothioates display reduced binding affinities
for RNA targets as well as a number of other liabilities that are
related to extensive nonspecific protein binding. Therefore,
newer second and third generation chemistries have been de-
vised to overcome these problems (Dean and Bennett, 2003;
Kurreck, 2003; Fig. 2).
Modifications of the 2
 
 
 
 position of the ribose ring lead to
RNA-like oligonucleotides, including fluro, 2
 
 
 
-
 
O
 
-methyl, and
2
 
 
 
-
 
O
 
-methoxy-ethyl (2
 
 
 
-MOE) oligonucleotides. These com-
pounds, especially the 2
 
 
 
-MOE versions, show significantly in-
creased binding affinity, good nuclease stability, and reduced
protein binding as compared with phosphorothioates. A recent
addition to the RNA-like oligonucleotides are the locked nu-
cleic acids (LNAs), where the ribose 2
 
 
 
-oxygen connects with
the 4
 
 
 
-carbon; these molecules have extraordinarily high RNA
binding affinities (Petersen and Wengel, 2003). A variety of
other oligonucleotide chemistries have been developed, includ-
ing sugar ring alterations such as anhydrohexitol nucleic acids
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(HNAs; Kang et al., 2004), as well as backbone modifica-
tions such as peptide nucleic acids, methyl phosphonates,
and morpholino nucleic acids, all of which provide uncharged
oligomers (Kurreck, 2003). Each of these novel oligonucle-
otides displays excellent binding affinity and resistance to deg-
radation. However, none of the RNA-like oligonucleotides
support significant RNaseH activity, and nor do HNAs, peptide
nucleic acids, methyl phosphonate, or morpholino backbones.
Fortunately, there is a simple solution to this conundrum: the
use of gapmer oligonucleotides. Gapmers contain a central
sequence of five to eight phosphodiester or (more usually)
phosphorothioate residues flanked by 5
 
 
 
 and 3
 
 
 
 sequences
drawn from the RNA-like or backbone-modified chemistries.
The gapmers can fully support RNaseH activity while retaining
many of the desirable properties of the modified oligonucle-
otides, including high RNA binding, nuclease resistance, and
low protein binding, thus leading to enhanced potency and
reduced toxicity.
The very lack of RNaseH stimulation displayed by many
second/third generation homooligonucleotides makes them ap-
propriate choices for an antisense strategy involving the alter-
ation of RNA splicing. Several years ago, Sierakowska et al.
(1996)
 
 
 
demonstrated that antisense oligonucleotides could cor-
rect the splicing of an aberrantly spliced thalassemic 
 
 
 
-globin
message. This seminal observation opened the door to many
experimental and therapeutic possibilities because 
 
 
 
60% of
human genes are alternatively spliced. Obviously, splice-site
correction requires the use of antisense oligonucleotides that do
not degrade RNA; thus, RNA-like and backbone-modified
compounds have been very valuable in this context. A variety
of chemically modified oligonucleotides have been used to cor-
rect the splicing of introduced or endogenous genes in cell cul-
tures as well as in vivo (Sazani and Kole, 2003). Antisense
manipulation of splice-site selection is unique in that either
down- or up-regulation of the target mRNA can be pursued.
For example, in the thalassemic case, it is increased expression
of a normal 
 
 
 
-globin message that is desired; up-regulation
was also desired in a recent study that used LNA oligonucle-
otides to correct the splicing of the Duchenne muscular dystrophy
gene (Aartsma-Rus et al., 2004).
 
Efficacy and selectivity.  
 
In pharmacological
terms, efficacy relates to the magnitude of the effect on the tar-
get, whereas selectivity relates to the uniqueness of the effect
on target versus nontarget entities. It is obviously desirable to
use antisense oligonucleotides with the highest efficacy and
greatest selectivity possible so as to attain a maximal effect on
the expression of the target gene with minimal off-target or
other side effects. High efficacy is often associated with high
potency; that is, with effects at low concentrations. The po-
tency of an antisense oligonucleotide is determined by many
factors. Some are innate to the oligonucleotide, and some are
associated with the target gene and the cell type under study.
High affinity base pairing is an important contribution to po-
tency. However, the ability of an antisense oligonucleotide to
bind to RNA in a cell also depends on the secondary structure
of the RNA, as well as on protein binding that may block ac-
cess of the oligonucleotide (Dean and Bennett, 2003; Vickers
et al., 2003). It is also important to remember that antisense
processes are enzymatically mediated; thus, variations in the
relative abundance of RNaseH (or proteins involved in splic-
ing) mean that an antisense compound may have variable ef-
fects in different cells. Finally, the efficiency of intracellular
delivery is a key issue. Most delivery techniques for antisense
(or small interfering RNA [siRNA]) oligonucleotides result in
only a fraction of the cell population attaining useful intracellu-
lar levels of the oligonucleotide. In many cases, delivery is the
key determinant of efficacy. Thus, in our experience, there is
often a strong correlation between the fraction of the viable cell
population that displays intracellular oligonucleotides and the
degree of reduction of the target message and protein. Despite
these various caveats, good progress has been made in creating
antisense oligonucleotides that are quite potent and effective.
For example, gapmers with MOE, HNA, or LNA 5
 
 
 
- and 3
 
 
 
-
flanking sequences have been efficacious in cell cultures when
used at low nanomolar levels (Alahari et al., 1998; Petersen
and Wengel, 2003; Vickers et al., 2003; Kang et al., 2004).
Figure 1. Mechanisms of antisense and
siRNA action. (left) Antisense oligonucleotides
are usually delivered to cells by some form of
transfection. The most common mechanism of
antisense action is RNaseH-mediated RNA
degradation subsequent to the binding of anti-
sense to its complement in the mRNA target.
This takes place in the nucleus. (right) siRNA
oligonucleotides can be delivered by transfec-
tion. Alternatively, hairpin RNAs can be ex-
pressed from plasmids or viral vectors (usually
from pol III promoters) and are cleaved by the
Dicer nuclease to siRNAs/miRNAs. A single
strand of the siRNA is loaded on to the RISC
complex, where it can cleave a target mRNA
with a near perfect complementarity. An
miRNA with partial mismatches can bind to an
mRNA and cause inhibition of translation.
Both types of processes take place in the cyto-
plasm. Ago 2, Argonaute 2. 
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Another key parameter is selectivity. One wishes to
down-regulate the message and protein levels of the gene of
interest and no other gene; however, most efforts fall far short
of this goal. Approaches for evaluating the selectivity of anti-
sense (or siRNA) oligonucleotides have been rapidly evolving.
Previously, selectivity was often assumed if (a) mismatched or
scrambled oligonucleotides were without effect on the target
or (b) the oligonucleotide failed to affect common nontarget
proteins (actin and tubulin). However, this limited and sim-
plistic approach is inadequate, and a few recent studies have
used DNA array technology as a more stringent means of eval-
uating specificity.
There are two aspects to the selectivity problem. The first
relates to the highly interconnected nature of the cellular econ-
omy and represents an essentially unavoidable situation. Obvi-
ously, an agent that reduces the expression of a key regulatory
protein will have an impact on many of its downstream effec-
tors. A good example of this comes from a DNA array study of
an antisense oligonucleotide that was directed against a subunit
of protein kinase A; manipulation of this key regulatory protein
affected numerous downstream genes (Cho et al., 2001). In
contrast, an antisense molecule targeting the 
 
MDR1
 
 gene,
which has fewer downstream connections, resulted in a much
smaller number of nontarget genes being affected (Astriab-
Fisher et al., 2002b). It is clear, however, that antisense oligo-
nucleotides cause effects on gene expression that are unrelated
to their suppression of the target gene (Astriab-Fisher et al.,
2002b; Eder et al., 2003).
A second, more controllable, aspect of selectivity relates
to the inappropriate degradation of nontarget RNAs and other
side effects. This issue can largely be addressed by proper oligo-
nucleotide design (Crooke, 2000; Sczakiel, 2000). For example,
it is obviously important to use a computer algorithm to make
sure that the targeted sequence is unique to the gene of interest.
Furthermore, the use of an oligonucleotide that can sustain
RNaseH activity along its entire length is problematic because
mRNAs, which have partial matches, can recruit the nuclease,
leading to off-target degradation (Lebedeva and Stein, 2001).
This issue is best addressed by the use of gapmers that contain
only a short segment capable of supporting RNaseH. Inappro-
priate side effects can also occur independently of RNA degra-
dation. As mentioned, oligonucleotides rich in phosphorothioate
residues bind strongly to many cell proteins and can potentially
interfere with their function (Lebedeva and Stein, 2001). In ad-
dition, some single-stranded oligonucleotides can form three-
dimensional stem–loop structures that act as aptamers; that is,
they can bind to protein receptors in a manner similar to drug
molecules, thus causing biological effects (Potti et al., 2004).
Finally, oligonucleotides containing CpG motifs can bind to
Toll-like receptors, leading to the inappropriate activation of
innate immune responses (Krieg, 2002).
Another issue that relates to both potency and selectivity
involves the mode of delivery of the oligonucleotide (Astriab-
Fisher et al., 2002a). Interestingly, there is a striking and unex-
plained difference between cell cultures, in which the use of a
delivery agent is required to attain antisense effects, and the sit-
uation in animals, in which effects can be achieved with “free”
oligonucleotides (Juliano and Yoo, 2000). In cell cultures, vari-
ous commercially available polycationic lipids or polymer
preparations can be used for transfection (Thierry et al., 2003).
Other approaches, such as conjugates of oligonucleotides with
cell-penetrating peptides, have also been effective (Astriab-
Fisher et al., 2002a; Morris et al., 2004; Moulton et al., 2004).
It is important to note that most of the delivery technologies
Figure 2. Chemical modifications of antisense oligo-
nucleotides. The structures of several important forms of
antisense oligonucleotides are illustrated. Phosphorothio-
ates can be considered first generation–modified oligonu-
cleotides, whereas additionally modified compounds that
retain the carbohydrate–phosphate backbone can be
considered second generation (e.g., 2 -O-methoxy-ethyl
oligonucleotides), and compounds with alternative back-
bones (e.g., peptide nucleic acids) can be considered
third generation. 
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commonly used, including cationic lipids, cationic polymers,
and electroporation, are inherently toxic to cells (Juliano and
Yoo, 2000) and that transfection reagent effects are sometimes
manifested as nonspecific changes in gene expression (Omidi
et al., 2003).
 
Antisense in the cell biologist’s toolkit.
 
The following is a possible approach to incorporate antisense
technology into your gene regulation toolkit. First, decide on the
type of oligonucleotide you will use; if you wish to knockdown
an mRNA, then a phosphorothioate gapmer is a good place to
start. The 5
 
 
 
 and 3
 
 
 
 “wings” flanking the gap could use any of
several chemistries, but 2
 
 
 
-
 
O
 
-methyl gapmers are readily avail-
able commercially and often work well (Table S1, available at
http://www.jcb.org/cgi/content/full/jcb.200501053.DC1). Next,
you will need to design a number of oligonucleotides that are
complementary to your target, essentially doing an “RNA
walk.” Because only 
 
 
 
1/10 of oligonucleotides are effective
(Lebedeva and Stein, 2001), choosing 
 
 
 
20 to test is reasonable.
Most investigators use 15–20-mer oligos, although there are ar-
guments that shorter oligonucleotides are actually more spe-
cific. Software such as Oligo 6 can enhance antisense design by
finding sequences that have duplex melting temperatures well
above 37
 
 
 
C and that are not self complementary. The oligonu-
cleotides will then need to be screened for effectiveness. One
simple approach is to use a commercial in vitro transcription kit
to generate target mRNA, and then add the oligonucleotides to
be tested and 
 
Escherichia coli
 
 RNaseH. Degradation of mes-
sages can be quantitated by Northern blot or by real-time PCR.
This approach is still somewhat artificial, and perhaps the surest
approach is to transfect the oligonucleotides into the cell type of
interest, and then measure the extent of target mRNA knock-
down. A reasonable goal would be to attain an 80–90% reduction
of target messages by using concentrations of oligonucleotides in
the 10–100 nM range. Significant reduction of mRNA levels
usually takes place within 1 d after transfection. Although the
investigator’s goal may be to attain a biological effect and/or to
knockdown a protein, it is vital to also test antisense oligonu-
cleotides for their actions at the message level because, as dis-
cussed above, nonantisense effects can also occur at the protein
and overall cell function levels. Once a promising antisense se-
quence is chosen, it is important to perform a number of con-
trols. This includes testing the effects of scrambled, mis-
matched, or irrelevant sequences on the target message as well
as evaluating the effect of the selected antisense on nontarget
mRNAs. The most stringent way to do this is to use DNA ar-
rays; however, at minimum, several nontarget messages should
be evaluated.
 
siRNA
 
The explosive growth of studies on RNA interference has pro-
vided a fascinating picture of how RNA molecules can partici-
pate in multiple endogenous gene regulatory processes. Starting
with work in plants, fungi, and lower animals but with increas-
ing emphasis on mammalian systems, investigators have found
innate RNA-mediated mechanisms that regulate mRNA stabil-
ity, message translation, and chromatin organization (Mello
and Conte, 2004). Furthermore, exogenously introduced long
double-stranded RNA (dsRNA) is an effective tool for gene si-
lencing in a variety of lower organisms. However, in mammals,
long dsRNAs elicit highly toxic responses that are related to
the effects of viral infection and interferon production (Wil-
liams, 1997). To avoid this, Elbashir et al. (2001) initiated the
use of siRNAs composed of 19-mer duplexes with 5
 
 
 
 phos-
phates and 2 base 3
 
 
 
 overhangs on each strand, which selec-
tively degrade targeted mRNAs upon introduction into cells.
 
Basic mechanisms.  
 
The action of interfering
dsRNA in mammals usually involves two enzymatic steps
(Fig. 1). First, Dicer, an RNase III–type enzyme, cleaves
dsRNA to 21–23-mer siRNA segments. Then, RNA-induced
silencing complex (RISC) unwinds the RNA duplex, pairs one
strand with a complementary region in a cognate mRNA, and
initiates cleavage at a site 10 nucleotides upstream of the 5
 
 
 
 end
of the siRNA strand (Hannon, 2002; Paddison and Hannon,
2002; Dorsett and Tuschl, 2004). This process takes place in
the cytoplasm. In mammals, the Argonaute 2 protein seems to
be the key component of the RISC complex responsible for
mRNA cleavage (Liu et al., 2004). Short, chemically synthe-
sized siRNAs in the 19–22 mer range do not require the Dicer
step and can enter the RISC machinery directly. It should be
noted that either strand of an RNA duplex can potentially be
loaded onto the RISC complex, but the composition of the oli-
gonucleotide can affect the choice of strands. Thus, to attain se-
lective degradation of a particular mRNA target, the duplex
should favor loading of the antisense strand component by hav-
ing relatively weak base pairing at its 5
 
 
 
 end (Khvorova et al.,
2003; Schwarz et al., 2003; Meister and Tuschl, 2004). In addi-
tion to mRNA cleavage, RISC complexes can also regulate ex-
pression at the translational level; the discovery of a large
number of micro-RNAs (miRNAs) as endogenous regulatory
components has provided insights into these events (Bartel,
2004). RISC–miRNA complexes inhibit translation by interact-
ing with sites in the 3
 
 
 
 regulatory regions of mRNA. Although
siRNA-mediated message cleavage requires a perfect or near
perfect sequence match, miRNA action requires a lesser degree
of complementarity (Bartel, 2004; Meister and Tuschl, 2004)
and, thus, is a possible source of off-target effects at the protein
level. Although there has been extensive work performed
on the intracellular processing of antisense oligonucleotides
(Juliano and Yoo, 2000; Thierry et al., 2003), this is just begin-
ning for siRNAs. However, at least one study suggests an inter-
esting correlation between subcellular localization and effect
(Chiu et al., 2004).
Exogenous siRNAs can be provided as synthesized oligo-
nucleotides or expressed from plasmid or viral vectors (Paddi-
son and Hannon, 2003; Hannon and Rossi, 2004). In the latter
case, precursor molecules are usually expressed as short hair-
pin RNAs (shRNAs) containing loops of 4–8 nucleotides and
stems of 19–30 nucleotides; these are then cleaved by Dicer to
form functional siRNAs. Although a variety of vector designs
are possible, in most cases pol III–dependent promoters from
mouse U6 small nuclear RNA
 
 
 
or human RNaseP are used, and
the shRNA is terminated by a series of Ts that comprise a stop
signal. Inducible forms of pol III siRNA vectors have also been
reported (van de Wetering et al., 2003; Hosono et al., 2004). 
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Many vectors have been used to express shRNAs; these
include lentiviruses (Sumimoto et al., 2005), adenoviruses
(Hosono et al., 2004), adeno-associated viruses (Xia et al.,
2004; Xu et al., 2005), retro viruses (Yang et al., 2003), and
transposons (Heggestad et al., 2004). In some cases, pol II–
driven vectors have been used, including ones with tissue spec-
ificity, but it is not clear that these vectors are as potent as their
pol III counterparts (Song et al., 2004).
The fact that shRNA can be deployed in a vector context
opens opportunities to create large libraries of shRNAs for use
in screening and genome-wide studies (Hannon and Rossi,
2004). There have been a number of approaches to this, in-
cluding the coordinated development of large human and
mouse siRNA libraries that are bar coded for convenient iden-
tification (Paddison et al., 2004). Library shRNA strategies
have been used to identify new elements of the p53 pathway,
the NFkB pathway, and PI-3-kinase signaling (Berns et al.,
2004; Hsieh et al., 2004; Zheng et al., 2004). New approaches
to the rapid generation of shRNA libraries from cDNAs have
also been developed, such as the restriction enzyme–generated
siRNA system (Sen et al., 2004) and others (Luo et al., 2004;
Shirane et al., 2004).
 
siRNA design and chemical modifications.
 
Currently, there is a great deal of interest in identifying and de-
signing highly effective siRNAs, including the use of chemical
modifications to improve stability or potency. Current (imper-
fect) knowledge of design has been embedded in various com-
puter algorithms that examine the target mRNA and predict ef-
fective siRNA sequences. Some of the design elements include
G/C content, lack of internal repeats, low duplex stability at the
5
 
 
 
 antisense terminus (as discussed above), and BLAST search-
ing to ensure uniqueness (Reynolds et al., 2004). Various com-
mercial suppliers of siRNA have such software on their web-
sites, but excellent nonproprietary tools are also beginning to
appear (Cui et al., 2004). An important unresolved issue in
siRNA design is the degree to which RNA folding and protein
binding influence the effectiveness of siRNAs (Dorsett and
Tuschl, 2004). Some studies have suggested that siRNA action
is relatively independent of such factors, whereas others have
indicated that siRNA, like antisense, is highly influenced by
RNA structure (Kretschmer-Kazemi Far and Sczakiel, 2003;
Vickers et al., 2003).
siRNAs are tolerant of a considerable degree of chemical
modification (Harborth et al., 2003), although some alterations
cause a loss of activity (Chiu and Rana, 2003). In general,
sense strands and 3
 
 
 
 regions are more amenable to modifica-
tion, whereas the 5
 
 
 
 region on the antisense strand and the cen-
tral region are more sensitive (Chiu and Rana, 2003; Czauderna
et al., 2003; Hall et al., 2004). The importance of chemical
modifications is exemplified by a recent study of siRNA effects
in animals. In the study, partial phosphorothioate backbone, 2
 
 
 
-
 
O
 
-methyl sugar modifications, and 3
 
 
 
 cholesterol-protected
sense strands were used, resulting in significant protection
against the 3
 
 
 
 exonuclease activity that ordinarily rapidly de-
grades siRNAs in serum (Soutschek et al., 2004).
 
Efficacy and selectivity.  
 
RNA interference in
lower organisms is incredibly potent, with the introduction of a
few molecules of dsRNA leading to virtually complete gene si-
lencing (Sijen et al., 2001). However, in mammals, siRNA is
considerably less robust. Although there have been reports of
siRNA effects on mammalian cells at picomolar concentrations
(Hannon and Rossi, 2004; Hassani et al., 2005), this seems ex-
ceptional, and most studies find significant target knockdown
in the 10–100 nM range (Attwell et al., 2003; Mitra et al.,
2004; Xu et al., 2004). Similarly, although some studies have
reported virtual ablation of endogenous target messages, partic-
ularly when viral vectors were used (Chen et al., 2004), it is
more common to observe a 40–90% knockdown of messages
and proteins when siRNA oligonucleotides are transfected
(Hannon and Rossi, 2004). One very appealing feature of
siRNA technology is that it apparently is possible to efficiently
knockdown more than one target at the same time. There are a
few examples of this in the literature using either chemically
synthesized siRNAs (Fukuda et al., 2003; Mitra et al., 2004) or
using hairpin vectors (Yu et al., 2003; Gondi et al., 2004).
siRNA effects are usually thought to be extremely spe-
cific. For example, there are reports of siRNAs that discriminate
between wild-type and mutant forms of p53 or Ras, differing by
only a single base (Brummelkamp et al., 2002; Martinez et al.,
2002). However, in other cases, siRNA has been unable to
make such fine discriminations (Karasarides et al., 2004). In-
deed, the selectivity of siRNAs is currently rather controversial;
this is well discussed in a recent review (Dorsett and Tuschl,
2004). At the mRNA level, some reports have indicated that
siRNAs do not cause global changes in gene expression as
evaluated by DNA array analysis (Semizarov et al., 2003).
However, others find quite the opposite, with numerous off-
target effects (Jackson et al., 2003; Jackson and Linsley, 2004;
Persengiev et al., 2004) that include the silencing of nontar-
geted genes containing as few as 11 contiguous nucleotides of
identity. In addition to these effects at the message level, non-
specific actions can occur at the protein level via miRNA actions
on partially matched sequences (Doench et al., 2003; Saxena et
al., 2003; Dorsett and Tuschl, 2004; Hannon and Rossi, 2004;
Scacheri et al., 2004). Furthermore, although siRNAs were
conceived as a way of avoiding nonspecific, interferon-like ef-
fects in mammalian cells, there have been reports of such effects
(Sledz et al., 2003). Finally, single-strand breakdown products
of siRNA molecules can potentially stimulate changes in mes-
sage and protein expression that are related to innate immunity
via interactions with a Toll-like receptor on the cell surface
(Heil et al., 2004). Thus, siRNAs are often far from perfect in
terms of selectively silencing target genes.
 
siRNAs in the cell biologist’s toolkit.
 
One of the principle attractions of siRNA technology is the ease
of entry for the novice. An investigator can simply plug in the
target DNA sequence to any one of several vendor websites and
generate lists of candidate siRNAs. The vendor will then pro-
duce any or all of the candidates. Various types of chemical
deprotection and purification are offered, as is the choice of buy-
ing preduplexed double-stranded oligonucleotides or even pools
of gene-targeted oligonucleotides (Table S2, available at http://
www.jcb.org/cgi/content/full/jcb.200501053.DC1). Some com-
panies are also beginning to provide simple chemical modifica- 
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tions that enhance stability or effectiveness. siRNAs are usually
delivered to cells via cationic lipids or cationic polymer agents,
which are similar to those used for plasmid transfection, or via
electroporation. Although some delivery agents have been de-
veloped specifically for siRNAs, transfection strategies (and ef-
ficiencies) differ widely among various cell types and most often
need to be optimized experimentally. siRNA technology affords
another option in the form of vectors that express hairpin RNA
oligonucleotides. Several such vectors are now available com-
mercially. Although not universal, in many cases sequences that
work well as chemically synthesized siRNAs also work when
incorporated as stem–loop hairpins into vectors (although an ex-
tension of the stem might be advisable).
Once a set of siRNA oligonucleotides or vectors is cho-
sen, the effects on target messages and protein levels can be
studied by a variety of means, as described in the Antisense in
the cell biologist’s toolkit section. As with antisense and de-
signed transcription factors, it is vital to perform key controls
to ensure that selective RNA interference is actually taking
place. Clearly, it is important to examine levels of target and
nontarget mRNAs to ensure that selective message degrada-
tion is occurring. Ideally, this would include a broad screen
such as that provided by a DNA array; minimally, several non-
target moieties should be examined. The use of “irrelevant”
duplex RNA oligonucleotides can also be helpful in evaluating
selectivity. Another strategy that is often advocated is to
cotransfect an altered version of the target gene whose mes-
sage should not be an siRNA target because of silent mutations
at several bases. Because siRNAs can be quite potent, one
should try to work at the lowest doses possible so as to mini-
mize off-target effects. As mentioned above, although one
might aspire to effects at picomolar levels, more common,
good quality siRNAs work at the 10–50 nM level. A recent re-
view provides another useful guide to practical applications of
siRNAs (Elbashir et al., 2002).
 
Designed transcription factors
Basic mechanisms.  
 
Transcription factors (TFs) are
typically modular proteins containing a DNA-binding domain
that is responsible for the specific recognition of base se-
quences and one or more effector domains that can activate or
repress transcription. TFs interact with chromatin and recruit
protein complexes that serve as coactivators or corepressors.
Important coactivators include the CBP–p300 complex that is
involved in transcriptional activation, accompanied by histone
modifications, the SWI–SNF chromatin remodeling complex,
and the Mediator complex that links TFs to the basal transcrip-
tion machinery. Corepressors include Sin3 and NuRD com-
plexes, which contain histone deacetylases that convert nucleo-
somes to a transcriptionally incompetent state (Jepsen and
Rosenfeld, 2002; Kadonaga, 2004).
In the creation of new transcription factors, novel DNA-
binding domains are obtained by a library screening process;
these are then combined with well-known transactivating or re-
pressor domains to form functional designed TFs (Pabo et al.,
2001; Beerli and Barbas, 2002; Falke and Juliano, 2003;
Jamieson et al., 2003; Blancafort et al., 2004). Commonly
used examples of transactivators include domains from the
herpes virus VP16 protein or from the NF
 
 
 
B p65 subunit,
whereas the Krupple-associated box and mSin3 interaction do-
main modules are frequently used as repressors. Much of the
work to date on designed transcription factors has used the
Cys2–His2 zinc finger (Zif) as a DNA-binding entity. A typical
C2H2 Zif is a compact module of 
 
 
 
30 amino acids, stabilized
by the zinc ion, and is arranged as two 
 
 
 
 sheets and an 
 
 
 
-helix,
with the helix being the primary DNA recognition moiety. The
utility of the C2H2 Zif in TF design is based on the modular
nature of Zif–DNA interaction and on the fact that the relation-
ship between protein structures and base recognition is well un-
derstood. Thus, amino acids at positions –1 to 6, with respect to
the start of the 
 
 
 
-helix, fit into the DNA major groove and me-
diate the interaction essentially by recognizing a 3
 
 
 
 base motif;
the residues at positions –1, 3, and 6 directly interact with the
3
 
 
 
, central, and 5
 
 
 
 bases of a triplet on one DNA strand. Al-
though additional base and backbone interactions can occur, to
a first approximation, the Zif–DNA interaction is modular,
with each Zif recognizing a three-base site. This allows the
ready creation of polydactyl multi-Zif proteins that can recog-
nize long stretches of DNA and, thus, provide highly selective
tools for gene manipulation. For example, a 6-Zif protein rec-
ognizing 18 bases would theoretically be able to uniquely bind
its target within a pool of almost 70 billion base pairs (Beerli
and Barbas, 2002).
 
Zif selection strategies.  
 
Zif modules with
novel DNA recognition abilities can be obtained by peptide
combinatorial library strategies such as phage display. Typi-
cally, three Zifs are displayed on the phage surface; two of
them are fixed, whereas the third is randomized at some or all
of the key residues at positions –1 to 6 (Choo and Klug, 1994;
Rebar and Pabo, 1994). Phages are then screened against an
oligonucleotide containing the target sequence that is immobi-
lized on a support. Phage display is a powerful strategy because
it allows the screening of large libraries (
 
 
 
10
 
9
 
 combinations).
However, the screening process involves “naked” oligonucle-
otides rather than chromosomal DNA. For that reason, some
groups have used in vivo screening strategies, including yeast
one-hybrid (Cheng et al., 1997; Bartsevich and Juliano, 2000)
and bacterial two-hybrid (Joung et al., 2000) selections in order
to seek Zifs that will effectively target genes in chromatin.
Whether using phage display or other approaches, several
rounds of selection can often lead to a novel Zif with the ability
to recognize virtually any triplet of the form GNN or ANN
(triplets starting with a pyrimidine are more difficult to obtain;
Dreier et al., 2001).
At this point, the process of building a novel multi-Zif
protein can follow either of two routes. One strategy is parallel
selection (Fig. 3); this is founded on the idea that Zifs are mod-
ular, and, thus, individual Zifs, which are selected for recogni-
tion of specific triplets, can be strung together to recognize
longer regions of DNA (Beerli and Barbas, 2002). A second
strategy is serial selection; this approach takes account of the
fact that the modularity of Zifs is not perfect. Serial selection,
as its name implies, involves starting with one novel Zif, and
then screening additional Zif modules that are optimized in 
EPIGENETIC MANIPULATION OF GENE EXPRESSION • JULIANO ET AL.
 
853
 
terms of working well together (Isalan et al., 2001; Pabo et al.,
2001). Although there are reasons for thinking that the serial
selection strategy may ultimately provide superior multi-Zif
proteins, it is a slow and cumbersome approach, whereas the
more rapid parallel selection strategy has, in practice, yielded
very effective novel TFs.
There has been substantial activity in the designed TF field
over the last few years, and, at this point, several groups have
now established large repertories of C2H2 Zifs with known bind-
ing specificities. In some cases, these Zif repertories are avail-
able to the research community (for example, at http://
www.scripps.edu/research/faculty.php?tsri_id
 
 
 
900), thus obvi-
ating the need to undertake extensive screening. An exciting re-
cent development is the advent of “libraries of libraries” that
comprise collections of modified Zifs targeting multiple three-
base sites that are then randomly assembled into multi-Zif TFs.
These libraries can be transfected into mammalian cells, which
can then be screened for a phenotype or for up- or down-regula-
tion of a particular gene product (Blancafort et al., 2003; Hurt et
al., 2003; Magnenat et al., 2004), thus providing a strategy that is
very comparable to the siRNA libraries discussed above. An ad-
vantage of this approach is that it directly seeks multi-Zif TFs that
function well in a chromosomal context. Once a desirable Zif-TF
is identified, its expression in cells can be regulated in a variety of
ways. Inducible expression systems, including those based on Tet
or ecdysone, can be used (Beerli and Barbas, 2002; Xu et al.,
2002). Alternatively, chemical ligands that regulate the function
rather than the expression of TF can be used (Lin et al., 2003).
 
Efficacy and selectivity.  
 
Properly designed multi-
Zif TFs can be very efficacious. Thus, 
 
 
 
90% reduction in
endogenous message and protein levels has been obtained by
using designed repressors (Xu et al., 2002; Papworth et al.,
2003; Segal et al., 2004). A comparison of the potency of de-
signed TFs with antisense or siRNA oligonucleotides is difficult
because, unlike oligonucleotides, TFs are expressed endoge-
nously from vectors. However, designed TFs with binding af-
finities in the subnanomolar range are readily attained (Beerli
et al., 2000; Pabo et al., 2001), suggesting that rather low con-
centrations within the cell can produce strong effects. The
binding affinity of a Zif-TF to its DNA target can be substan-
tially altered by a single base change in the target (Wolfe et al.,
1999); however, some binding to “imperfect” sites may be tol-
erated (Segal et al., 2004). As with studies on antisense and
siRNA, evaluation of the selectivity of designed TFs in cells
has often been rather crude and simplistic. However, several
recent publications have used DNA arrays to obtain a more
comprehensive picture (Xu et al., 2002; Tan et al., 2003; Lee et
al., 2004). As with antisense, designed TFs that target key reg-
ulatory genes are likely to cause multiple changes in gene ex-
pression. That aside, however, designed TFs seem to be highly
selective when the target is not itself a key regulator, providing
strong regulation of target gene mRNA with lesser effects on a
few nontarget genes. Although it is conceivable that designed
TFs could have side effects as a result of protein–protein inter-
actions rather than transcriptional regulation, we are not aware
of any such reports.
Figure 3. Development of designed transcription
factors. Zinc-finger domains (Zifs) can be selected to
bind to any desired DNA triplet using a combinatorial
library strategy such as phage display. Individual Zifs
can be combined to make multi-finger proteins that
selectively bind to extended regions of DNA in the
promoter regions of genes. The addition of transacti-
vating or repressor domains allows positive or nega-
tive regulation of gene expression. N1–N9, various
bases (N* is the complement). A–C are triplets. Zif*
indicates Zifs selected from the library screening.
WT, wild type; AD, activation domain; RD, repressor
domain. 
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Designed TFs in the cell biologist’s tool-
kit.  
 
The use of designed TFs seems at first to be more
technically daunting than the use of antisense or siRNA. Al-
though this was true a few years ago, the existence of large
pools of designed Zifs has now made the TF strategy much
more accessible, as described in more detail elsewhere (Segal,
2002). For example, let’s assume that you wish to up- or down-
regulate a specific endogenous gene and that something is
known about the promoter region. A reasonable initial ap-
proach would be as follows. Scan the promoter for binding
sites for endogenous TFs (particularly ones that use Zifs as
DNA-binding domains, if possible). Sites that are accessible to
endogenous Zifs are likely within chromatin regions that are
also accessible to transfected designed TFs. Look for 15–18
base sequences near these regions that are G-rich (because
many existing Zifs recognize GNN sequences). Obtain infor-
mation on the availability of cDNAs for Zifs that match your
sequence. If available, the individual Zifs can be linked by con-
ventional PCR techniques to form a multi-Zif protein; a trans-
activator or repressor domain should also be included, and the
entire construct can be placed in a mammalian expression plas-
mid or in a viral vector. Note that there is a certain amount of
controversy about the best way to link multiple Zifs (Jamieson
et al., 2003); however, the consensus sequence of TGEKP of-
ten works well. The designed TF can now be directly trans-
fected into the cells of interest, and effects on gene expression
can be monitored at the message and protein levels. Obviously,
a number of controls are needed. These might include a vector
expressing a multi-Zif TF that binds to an irrelevant target, a
vector expressing only the transactivating domain or only the
multi-Zif, and an “empty” vector. Ultimately, more detailed
studies of specificity should include DNA array analysis.
 
A comparison of gene regulation 
technologies
 
There are advantages and liabilities with each of the technolo-
gies discussed above, and the choice of a tool by a cell biologist
might entail several considerations, including the overall goal
of the project, ease of use, cost, effectiveness, and selectivity.
At the most basic level, choices can be made based on intended
use. Designed transcription factors and antisense (via splice
modulation) can either up-regulate or down-regulate gene ex-
pression; siRNA is restricted to down-regulation. siRNA and
designed TFs can be expressed from viral or plasmid vectors,
potentially providing much more uniform delivery of the active
agent than can be achieved by simple transfection; antisense is
limited to delivery by transfection.
An important consideration is the ease of use, especially
for the novice. siRNA is clearly the winner here. The various
companies in this field have made it very simple to get started.
However, entry into the antisense arena is also basically quite
easy; one simply needs to design and order the oligonucleotides.
One possible difference is the number of compounds that need to
be screened to find an effective agent. As mentioned above, of-
ten 20 or more antisense oligonucleotides must be screened to
find one effective compound. With siRNA, it is often said that
the computer algorithms generate effective oligonucleotides at
the level of 1/2 to 1/4 (this is not always the case, however, and
in some instances, despite using the best available vendor algo-
rithms, we have screened dozens of siRNAs without getting an
effective compound). Entry into the designed TF area takes more
effort. Although a library of prefabricated Zifs may be available,
these still need to be assembled into multi-Zif proteins for effec-
tive DNA binding and then linked to repressor or transactivator
domains. One mitigating factor is that unlike the oligonucleotide
approaches, there is often not a great deal of screening with de-
signed TFs because they are created on a rational basis.
Cost is another important consideration. On a molar ba-
sis, siRNAs are substantially more expensive than antisense
oligonucleotides (unless very exotic modifications are re-
quested). For example (depending on the vendor), 200 nmol of
a 19-mer duplexed siRNA might cost $400, whereas 200 nmol
of a 19-mer phosphorothioate antisense compound might be
about $60, and a 2
 
 
 
-
 
O
 
-Me phosphorothioate gapmer could cost
about twice that. However, the need to screen more compounds
when using antisense than with siRNAs could offset the cost
differential. Designed TFs are free in terms of reagent costs;
however, substantial labor would go into the production of a
specific multi-Zif protein.
Each of these tools can be quite efficacious and potent for
gene regulation. As mentioned above, knockdowns of 90% or
more have been obtained with all of the approaches. Although
some investigators suggest that the IC50 levels for siRNAs are
100-fold or are lower than for antisense oligonucleotides (Dorsett
and Tuschl, 2004), this probably does not take into account recent
advances in antisense chemistry. We have observed similar levels
of message and protein reduction for commercial siRNAs and for
second or third generation antisense oligonucleotides when used
in the 10 nM range (Kang et al., 2004; Xu et al., 2004).
A key issue is selectivity: can one affect the target gene
with minimal effects on other genes? Here, the winner seems to
be designed TFs. Work from our laboratory and others has
shown that designed TFs can substantially alter target gene ex-
pression with minimal off-target effects, as evaluated by DNA
arrays (as long as a key regulatory protein is not the target; Xu
et al., 2002; Tan et al., 2003; Lee et al., 2004). In contrast, early
generation phosphorothioate oligonucleotides have numerous
off-target effects at the message and protein levels, probably
primarily as a result of their propensity to bind proteins. Gap-
mer antisense oligonucleotides with newer chemistries promise
to be more selective; however, these types of compounds have
yet to be stringently evaluated. siRNAs were originally thought
to be extremely specific. However, more recent findings sug-
gest that (in the pharmacologist’s lexicon) siRNAs can be
“dirty drugs.” Off-target effects at the message (siRNA) and
protein (miRNA) levels are possible, as is gene induction
through the innate immune system. This is not to say that
siRNA cannot be used in a relatively selective manner. How-
ever, investigators using siRNA must prove selectivity rather
than assuming it. Thus, although there is no magic bullet for
epigenetic gene regulation, a careful and skeptical approach to
using antisense, siRNA, or designed transcription factors may
provide the investigator with powerful and selective tools to
study the role of individual genes in cell biological processes. 
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